Determination of Organophosphorus Pesticides in Seawater by GC-FPD Using Two Columns

本文提出了一种GC-FPD测定海水中28种有机磷农药残留的新方法。采用双柱法,即选用DB-1701柱进行定性、定量分析,用HP-5柱验证。既发挥了FPD检测器灵敏、定量准确的优点,又利用了双柱法的定性功能。方法对各目标物均有良好的线性关系,回收率和RSD分别在70.2%~103.2%、8.7%~17.5%之间,适合于海洋水体中痕量有机磷农药的分析。A GC method has been developed to determine 28 kinds of OPPs in seawater simultaneously by GC-FPD.The columns were DB-1701 and HP5.The column DB-1701 used for analysis and the column HP-5 used for validate.The linear dynamic ranges were well.the recovery was from70.2 %～103.2 %,the RSD was from 8.7 %～17.5 %.The method was used for the determination of trace OPPs in sea water.国家863项目(项目编号:2003AA635180

颅内原发恶性淋巴瘤的MRI诊断(附12例报告)

目的　探讨颅内原发恶性淋巴瘤CT及MR的表现特征 ,以提高诊断准确率。方法　对 12例经手术病理证实的颅内原发恶性淋巴瘤的CT及MR表现进行回顾分析。结果　共检出 3 2个病灶 ,其中单发 9例 ,分别位于额、颞、顶叶深部脑白质 8例 ,位于颞叶表面 1例 ;多发 3例 ,病灶多位于深部脑白质。CT多表现为圆形或类圆形稍高密度灶 ,MRI表现为T1WI低或等信号 ,T2 WI为稍低信号。多数病灶周围有轻 -中度高信号水肿带 ,病灶边界尚清楚。增强扫描见所有病灶均有强化 ,2 3个 ( 72 .0 % )病灶呈均匀强化 ,18个 ( 5 6.2 5 % )病灶强化后出现缺口或凹陷改变。病理结果 :11例为非何杰金氏淋巴瘤 ,1例为浆细胞淋巴瘤。结论　尽管颅内原发恶性淋巴瘤的影像表现与其它颅内肿瘤如脑膜瘤、胶质瘤及转移瘤等有许多相似之处 ,但通过认真分析其影像特征 ,术前的正确诊断是有可能

Tween-80对铝酞菁荧光的增强和稳定作用

光动力学治疗(photodynamic therapy,PDT)是一种新兴的治疗癌症的方法。对比于传统疗法,PDT具有以下优点:毒性小、收效快[1],对肿瘤细胞具有相对选择性和组织特异性;冷光化学反应,不影响其他治疗,与手术、放疗和化疗等疗法相辅相成;可重复用药,无药物耐受性;治疗时间短,48～72 h即可发挥作用[2]。PDT包含3个可变参数:光敏剂、国家自然科学基金(81600537);;山西省回国留学人员科研资助项目(2017-123

The primary investigation of the value of whole body diffusion weighted imaging in diagnosis of metastatic tumor

背景与目的:随着临床上晚期肿瘤病例的增多,为了解治疗前、后全身转移瘤的大小及数量变化的实际情况,以往多采用分部位进行CT和(或)Mr扫描,少部分有条件的患者采用PET检查,但这些方法可能存在过多地暴露于射线、检查时间过长及经济负担过重等问题。因此,我们探讨磁共振的全身弥散加权成像(WHOlE bOdy dIffuSIOn WEIgHTEd IMAgIng,WbdWI)方法对肿瘤及转移灶的检出准确性及其临床应用的可行性。方法:对68例临床已发现原发肿瘤及多个转移灶或发现多个肿瘤病灶,但原发灶不明确的患者进行WbdWI检查,其中男性49例;女性19例。平均年龄61岁。68例均与CT和(或)MrI的检查结果进行比较,其中17例与PET的检查结果相比较。对病灶的检出率,以病灶长径大小分为:<1CM,≥1~<2CM,≥2~<3CM及≥3CM以上4组进行计数分析,同时,对不同部位间的病灶检出情况进行分析。结果:WbdWI对4组病灶的检出率分别为30%、78%、96%及100%。在各个部位的敏感性和准确性中以骨骼最高。对位于肺部小于1CM的病灶和位于颈部、盆腔小于2CM的淋巴结的诊断存在一定困难。结论:WbdWI对大范围的肿瘤病灶筛查是安全、简便、有效和经济的检查新方法。随着技术参数的进一步完善,WbdWI在发现和诊断全身多发肿瘤方面,具有良好的发展潜力。因此,本技术有望作为一种新的、效果好于PET的全身检查技术。Background and purpose:With the increased number of advanced tumors,it is important to evaluate the actual pre-and post-treatment changes in metastatic diseases,such as tumor size and tumor quantity.Previously,CT and/or MRI scan were usually applied,only a few patients could pay for PET(positron emition tomography).But there were several problems we should face,including redundantly exposure to radiation,too long verification time and heavy financial burden.Therefore we evaluated the application of whole body diffusion weighted imaging in diagnosing of tumor and metastatic tumor.Methods:sixty-eight patients(49 male,19 female,age from 29 to 84 years with mean age of 61 years) with a variety of tumors were investigated by combined CT and/or MRI scan,seventeen patients were compared with positron emition tomograph(PET).All tumors were classified into four groups,according to longest diameter of <1 cm,≥1-<2 cm,≥2-<3 cm and ≥3 cm.At the same time,the positive detection rates between different parts of the lesions were analyzed.Results:The detection rate of the four groups were 30%,78%,96% and 100%,respectively.The skeletal system had the highest sensitivity and accuracy in every part of body.There was difficulty in diagnosing lung cancer with longest diameter less than 1 cm as well as tumors located in neck and pelvic with longest diameter less than 2 cm.Conclusion:Whole body diffusion weighted imaging is secure,convenient,effective and economic for screening wide-ranging tumor focus.After improvement of parameters,WBDWI could be as a new effective whole body examination technique.厦门市科技计划项目(No:3502Z20074017

Y型聚乙二醇干扰素琢-2b注射液治疗HCV基因2/3型慢性丙型肝炎患者疗效和安全性的多中心随机对照试验研究

目的以标准剂量的聚乙二醇干扰素(Peg IFN)α-2a联合利巴韦林作为阳性对照,评价新型试验药物Y型Peg IFNα-2b注射液联合利巴韦林治疗2型/3型慢性丙型肝炎(CHC)患者的疗效和安全性。方法采用多中心、随机开放、阳性药对照的Ⅲ期临床试验,筛选符合要求的2型/3型CHC患者,按照2:1的比例随机分配到Y型Peg IFNα-2b组和Peg IFNα-2a组,同时口服利巴韦林,疗程24 w,停药随访24 w。采用Abbott Real Time HCV Genotype II检测HCV基因型,采用Cobas Taq Man实时定量PCR法检测血清HCV RNA水平。详细记录不良事件。主要疗效指标为持续病毒学应答(SVR),并进行非劣效检验。结果本试验实际入组2型/3型CHC患者255例,实际治疗241例。全分析集(FAS)数据显示,158例试验组和83例对照组患者SVR分别为85.4%(95%CI 79.94%~90.94%)和79.5%(95%CI 70.84%~88.20%,P=0.2402);对符合方案分析集(PPS)人群分析显示,试验组和对照组患者SVR分别为87.9%(95%CI 82.45%~93.27%)和85.9%(95%CI 77.82%~94.01%,P=0.7060),率差的95%可置信区间均符合非劣效标准;对PPS人群分析显示,85.8%受试者获得了早期病毒学应答(RVR),RVR的阳性预测值为90.1%;试验组和对照组不良事件发生率相似,分别为95.6%和95.2%,严重不良事件发生率分别为3.8%和3.6%。结论应用Peg IFNα联合利巴韦林治疗2型/3型CHC患者,新型试验药物Y型Peg IFNα-2b具有与对照药物Peg IFNα-2a相似的疗效和安全性。国家科技部“十二五”重大专项(编号:2012ZX10002-003)；“重大新药创制”十二五科技重大专项(编号:2012ZX09303019)